Literature DB >> 25488153

Blood-brain barrier permeability and brain uptake mechanism of kainic acid and dihydrokainic acid.

Mikko Gynther1, Aleksanteri Petsalo, Steen H Hansen, Lennart Bunch, Darryl S Pickering.   

Abstract

The glutamatergic neurotransmitter system is involved in important neurophysiological processes and thus constitutes a promising target for the treatment of neurological diseases. The two ionotropic glutamate receptor agonists kainic acid (KA) and dihydrokainic acid (DHK) have been used as research tools in various in vivo central nervous system disease models in rodents, as well as being templates in the design of novel ligands affecting the glutamatergic system. Both molecules are highly polar but yet capable of crossing the blood-brain barrier (BBB). We used an in situ rat brain perfusion technique to determine the brain uptake mechanism and permeability across the BBB. To determine KA and DHK concentrations in the rat brain, simple and rapid sample preparation and liquid chromatography mass spectrometer methods were developed. According to our results the BBB permeability of KA and DHK is low, 0.25 × 10(-6) and 0.28 × 10(-6) cm/s for KA and DHK, respectively. In addition, the brain uptake is mediated by passive diffusion, and not by active transport. Furthermore, the non-specific plasma and brain protein binding of KA and DHK was determined to be low, which means that the unbound drug volume of distribution in brain is also low. Therefore, even though the total KA and DHK concentrations in the brain are low after systemic dosing, the concentrations in the vicinity of the glutamate receptors are sufficient for their activation and thus the observed efficacy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25488153     DOI: 10.1007/s11064-014-1499-4

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  26 in total

1.  Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease?

Authors:  M Rosario Luquin; Laura Saldise; Javier Guillén; Silvia Belzunegui; Waldy San Sebastián; Amaya Izal; Pablo Garrido; Marianne Vázquez
Journal:  Exp Neurol       Date:  2006-06-27       Impact factor: 5.330

2.  Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction.

Authors:  Scott G Summerfield; Kevin Read; David J Begley; Tanja Obradovic; Ismael J Hidalgo; Sara Coggon; Ann V Lewis; Rod A Porter; Phil Jeffrey
Journal:  J Pharmacol Exp Ther       Date:  2007-04-03       Impact factor: 4.030

3.  Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery.

Authors:  J Cory Kalvass; Tristan S Maurer
Journal:  Biopharm Drug Dispos       Date:  2002-11       Impact factor: 1.627

4.  Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Authors:  Kelly M Mahar Doan; Joan E Humphreys; Lindsey O Webster; Stephen A Wring; Larry J Shampine; Cosette J Serabjit-Singh; Kimberly K Adkison; Joseph W Polli
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

5.  High-performance liquid chromatographic analysis of physiological amino acids in human brain tumors by pre-column derivatization with phenylisothiocyanate.

Authors:  A Battaglia; A Bertoluzza; F Calbucci; V Eusebi; P Giorgianni; R Ricci; R Tosi; V Tugnoli
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-06-25

6.  Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability.

Authors:  F Stain-Texier; G Boschi; P Sandouk; J M Scherrmann
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 7.  Subtype selective kainic acid receptor agonists: discovery and approaches to rational design.

Authors:  Lennart Bunch; Povl Krogsgaard-Larsen
Journal:  Med Res Rev       Date:  2009-01       Impact factor: 12.944

Review 8.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

9.  Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling.

Authors:  Björn Bauer; Anika M S Hartz; Anton Pekcec; Kathrin Toellner; David S Miller; Heidrun Potschka
Journal:  Mol Pharmacol       Date:  2007-12-19       Impact factor: 4.436

10.  Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease.

Authors:  Benjamin R Miller; Jenelle L Dorner; Kendra D Bunner; Thomas W Gaither; Emma L Klein; Scott J Barton; George V Rebec
Journal:  J Neurochem       Date:  2012-03-28       Impact factor: 5.372

View more
  4 in total

1.  Toxicokinetics and Physiologically Based Pharmacokinetic Modeling of the Shellfish Toxin Domoic Acid in Nonhuman Primates.

Authors:  Jing Jing; Rebekah Petroff; Sara Shum; Brenda Crouthamel; Ariel R Topletz; Kimberly S Grant; Thomas M Burbacher; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2017-11-17       Impact factor: 3.922

2.  Ca2+ Signals in Astrocytes Facilitate Spread of Epileptiform Activity.

Authors:  Kjell Heuser; Cecilie G Nome; Klas H Pettersen; Knut S Åbjørsbråten; Vidar Jensen; Wannan Tang; Rolf Sprengel; Erik Taubøll; Erlend A Nagelhus; Rune Enger
Journal:  Cereb Cortex       Date:  2018-11-01       Impact factor: 5.357

3.  Glutamatergic Activation of Neuronostatin Neurons in the Periventricular Nucleus of the Hypothalamus.

Authors:  Sema Serter Kocoglu; Duygu Gok Yurtseven; Cihan Cakir; Zehra Minbay; Ozhan Eyigor
Journal:  Brain Sci       Date:  2020-04-06

4.  Immunohistochemical Evidence for Glutamatergic Regulation of Nesfatin-1 Neurons in the Rat Hypothalamus.

Authors:  Duygu Gok Yurtseven; Sema Serter Kocoglu; Zehra Minbay; Ozhan Eyigor
Journal:  Brain Sci       Date:  2020-09-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.